secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001564590-22-037280
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent Q3 net loss $19.7M; NVL-520 shows proof-of-concept; $264.5M offering extends runway into H2 2025
--------------------------------------------------------------------------------

- Q3 net loss $19.7M ($0.41/sh); cash $240.1M; with $264.5M offering extends runway into H2 2025.
- NVL-520 Phase 1 data: no DLTs, activity in heavily pre-treated ROS1+ NSCLC including G2032R and brain metastases.
- NVL-655 (ALK inhibitor) enrollment in Phase 1 ALKOVE-1 trial progressing; new preclinical data shows activity against compound mutations.
- NVL-330 (HER2 exon 20) preclinical data demonstrates potency, selectivity, brain penetration; potential best-in-class.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000156459022037280/0001564590-22-037280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000156459022037280/nuvl-8k_20221110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-037280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer